Middle East & Africa Hematuria Treatment Market

Market Introduction

Hematuria is a medical condition where presence of blood is found in the urine. Generally, urine does not contain RBC and hence this can result in serious issue that may also cause kidney stones, urinary tract infection and other inherited diseases.

Moreover, the high prevalence hematuria associated indications is expected to bolster the market growth during the forecast period. However, undiagnosed cases of associated indications limit the growth of the Middle East & Africa hematuria treatment market.

In the MEA region, the number of patients hospitalized in intensive care units (ICU) is rising, as is the number of pharmaceuticals prescribed, creating many diagnostic and therapeutic problems for already overburdened healthcare systems. COVID-19 symptoms are mostly seen in the pulmonary system, but urogenital manifestations and/or consequences are given special attention. The risk of serious infection is higher in older patients with CKD, and AKI is linked to a high fatality rate. Thus, it was necessary to monitor the kidney function of patients with severe COVID-19, and CRRT for protecting kidney function and cytokine elimination for critically ill patients was critical to improving recovery. COVID-19 infection, on the other hand, appears to have ramifications for the urogenital tract. When treating COVID-19, urogenital organs should be considered.

Market Overview and Dynamics

The Middle East & Africa hematuria treatment market is projected to reach US$ 46.8 million by 2028 from US$ 42.0 million in 2021; it is anticipated to grow at a CAGR of 1.5% from 2021 to 2028. Chronic kidney disease (CKD) is a common and life-threatening condition that affects a larger population. There are various types of CKDs, such as kidney stones, glomerulonephritis, polycystic kidney disease, and urinary tract infections. CKD is one of the key causes behind the prevalence of hematuria. In addition, the prevalence of UTI among women over 65 years of age is about 20% compared to the overall population, which is about 11%. Currently, the Middle East & Africa hematuria treatment market is gaining significantly from the increasing prevalence of associated indications.

Key Market Segments

In terms of type, the macroscopic hematuria segment accounted for the largest share of the Middle East & Africa hematuria treatment market in 2020. In terms of treatment, the drugs segment accounted for the largest share of the Middle East & Africa hematuria treatment market in 2020. In terms of indication, the urinary tract infection segment accounted for the largest share of the Middle East & Africa hematuria treatment market in 2020. In terms of end user, the hospitals segment accounted for the largest share of the Middle East & Africa hematuria treatment market in 2020.

Major Sources and Companies Listed

A few major primary and secondary sources referred to for preparing this report on the hematuria treatment market in Middle East & Africa are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are AstraZeneca, Bristol-Myers Squibb Company, F. HOFFMANN-LA ROCHE LTD., GlaxoSmithKline plc., Janssen Pharmaceuticals, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd, and Boehringer Ingelheim International GmbH.

Reasons to Buy Report

• To understand the Middle East & Africa hematuria treatment market landscape and identify market segments that are likely to guarantee a strong return
• To comprehend the ever-changing market landscape and stay ahead in competition
• To efficiently plan merger and acquisition, and partnership deals in the Middle East & Africa hematuria treatment market by identifying segments with the most promising probable sales
• To make knowledgeable business decisions from perceptive and comprehensive analysis of the market performance of various segments
• To obtain market revenue forecast of the Middle East & Africa hematuria treatment market based on various segments for the period 2021–2028

MIDDLE EAST & AFRICA HEMATURIA TREATMENT MARKET SEGMENTATION

By

• Drugs
• Therapies
• Others

By Indication

• Urinary Tract Infections
• Kidney Stones
• Urethritis
• Blood Cancer
• Bladder Stones
• Prostate Cancer
• Cystitis
• Trauma
• Vigorous Exercise
• Polycystic Kidney Disease
• Endometriosis
• Menstruation

By Type

• Macroscopic Hematuria
• Microscopic Hematuria
• Idiopathic Hematuria
• Jogger’s Hematuria

By End User

• Hospitals
• Clinics
• Ambulatory Surgical Centers (ASC's)
• Others

By Country

• Middle East & Africa
  • UAE
  • Saudi Arabia
  • South Africa
  • Rest of Middle East & Africa

Companies Mentioned

• AstraZeneca
• Bristol-Myers Squibb Company
• F. HOFFMANN-LA ROCHE LTD.
• GlaxoSmithKline plc.
• Janssen Pharmaceuticals
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Sun Pharmaceutical Industries Ltd
• Boehringer Ingelheim International GmbH

Middle East & Africa Hematuria Treatment Strategic Insights

Strategic insights for the Middle East & Africa Hematuria Treatment provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Middle East & Africa Hematuria Treatment Report Scope

Middle East & Africa Hematuria Treatment Regional Insights

The geographic scope of the Middle East & Africa Hematuria Treatment refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.